Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.
Aoyama Y, Ozaki Y, Kuno M, Kizawa R, Masuda J, Nishimura M, Kurata M, Inagaki L, Hosonaga M, Fukada I, Maeda T, Yoshida K, Yamashita N, Kobayashi T, Takano T, Ueno T
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.